Navigation Links
Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
Date:11/12/2012

ROCKVILLE, Md., Nov. 12, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the Company has entered into an agreement with Prev AbR LLC to acquire its clinical-stage and related beta-lactamase assets targeted for the prevention of Clostridium difficile (C. diff) infection, the leading cause of hospital acquired infections (HAI), that may occur secondary to treatment with antibiotics. The assets include a pre-Investigational New Drug (IND) package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and international patents intended to support an IND and Biologic License Application (BLA) with the FDA.

Beta-lactamase enzymes have the ability to degrade beta-lactam antibiotics that may be excreted into the GI tract. Beta-lactam antibiotics are a mainstay in hospital infection management and include both penicillins and cephalosporins. In 2011, an estimated 8.7 million Americans were administered intravenous beta-lactam antibiotics.[1] Utilizing the acquired biologic compounds, Synthetic Biologics intends to develop and commercialize a proprietary oral beta-lactamase enzyme product candidate, SYN-004. When co-administered with beta-lactam antibiotics in a hospital setting, it is expected that SYN-004 can preserve a patient's gastrointestinal (GI) microflora, thus preventing opportunistic C. diff infection (CDI).

C. diff Infection

In 2009, aggregate costs associated with CDI-related stays in the hospital were $8.2 billion in the U.S.[2] CDI is a global HAI in which the toxins produced by C. diff bacteria result in diarrhea (C. diff-associated diarrhea (CDAD)), and in the most serious cases, pseudomembranous colitis (erosion of the GI tract) that can lead to death. A major, unintended risk in the use of syste
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Taming mavericks: Stanford researchers use synthetic magnetism to control light
2. Synthetic Biologics Completes $10.8 Million Private Placement Financing
3. Synthetic Biologics Announces $10.8 Million Financing
4. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
5. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
6. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
7. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
8. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
11. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  HealthSouth Corporation (NYSE: ... of post-acute healthcare services, offering both facility-based and ... operations for the second quarter ended June 30, 2015. ... by strong volume growth in both segments and ... Jay Grinney, President and Chief Executive Officer of ...
(Date:7/29/2015)... Station, TX (PRWEB) , ... July 29, 2015 ... ... POD® designer, manufacturer and supplier, announces the launch of their 2nd generation cell ... to the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... ... 2015 , ... Brady (NYSE:BRC), a global leader in product ... align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard and the ... of an accurate label, and pictogram uses and meanings. , “With changes to ...
(Date:7/29/2015)... YORK , July 29, 2015  Therapath ... testing, announces increased partnerships with VA and Military ... Epidermal Nerve Fiber Density (ENFD) and Sweat Gland ... small fiber neuropathy ( https://therapath.com/skin ). ... Nerve Fiber Density (ENFD) on punch skin biopsy ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... SPEX ) reported that on July 21, 2008, ... the bid price of the,Company,s common stock for the ... minimum $1.00 per share required for continued listing,on NASDAQ. ... the Common Stock at,this time., Spherix has been ...
... July 23 Duska Therapeutics,Inc. (OTC Bulletin Board: ... comment a synopsis of a proposed Phase 3 ... U.S. Food and Drug Administration,s (the,"FDA") Division of ... communications with the FDA, including a face-to-face,meeting held ...
... July 23 NxStage Medical,Inc. (Nasdaq: NXTM ... announced ongoing public access to current summary,information derived ... (ESRD) who undergo hemodialysis at home on a ... the conventional regimen of therapy,received three times a ...
Cached Biology Technology:Spherix Receives NASDAQ Bid Price Deficiency Letter 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 2NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 3NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 4NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 5
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... historic meeting next week may decide the fate of tuna ... important marine resources. The Inter-American Tropical Tuna Commission ... 27 in Panama City, Panama, to reverse a trend ... of tuna stocks. Failure of the IATTC to compromise effectively ...
... in gaining major European Union funding to begin ... such as DNA, can be managed and made ... Centre for Integrated Genomic Medical Research (CIGMR), based ... a key role in developing the Biobanking and ...
... Worker Identification Credential (TWIC) Program, Ensures No ... MIAMI BEACH, Fla., June 17 ... high-performance solutions for trusted,credential assurance, reported that ... critical software to the Transportation Security Agency,s ...
Cached Biology News:Tuna populations at risk 2Manchester clears first hurdle in €170 million biobank building boom 2ID Solutions Awarded Full-Production Order for Fingerprint Processing Software for TWIC 2
... in Ham's F12K medium with 2 mM L-glutamine ... In order to keep the antigens in their ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... Stabilizer is an aqueous solution that contains ... chemicals in a PBS buffer (phosphate buffered ... product contains a combination of 0.02% methylisothiazolone ... StabilCoat Plus Stabilizer provides optimum performance for ...
... trays are disposable trays that ... that have been blotted onto ... eight 10.5 cm x 5 ... cut from blotted membrane and ...
Biology Products: